AbbVie Inc. (ABBV)
Price:
224.50 USD
( - -2.42 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
SRx Health Solutions Inc.
VALUE SCORE:
3
2nd position
Novo Nordisk A/S
VALUE SCORE:
9
The best
Johnson & Johnson
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
NEWS
First Look: Nvidia beats, Stellantis pivots, WBD bid war
gurufocus.com
2026-02-26 07:39:00Stock News Nvidia posts record quarter, upbeat outlook: Nvidia (NVDA) reported Q4 revenue of $68.13B with data center sales at $62.3B (91% of total) and guided
Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
seekingalpha.com
2026-02-26 07:30:11Merck & Co. (MRK) is upgraded to buy, driven by improving dividend cushion ratio (DCR) and robust FQ4 2025 earnings recovery. MRK's dividend safety strengthens, with a projected DCR of 2.57x for 2026, surpassing both its historical average and ABBV's outlook. AbbVie (ABBV) maintains strong results but faces DCR pressure from CAPEX plans, with a projected 2.19x DCR in 2026.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More
247wallst.com
2026-02-25 07:57:47Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a "Meltdown Monday." Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology... Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More.
AbbVie Inc. $ABBV Shares Bought by Empirical Asset Management LLC
defenseworld.net
2026-02-25 05:40:42Empirical Asset Management LLC increased its position in AbbVie Inc. (NYSE: ABBV) by 206.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,372 shares of the company's stock after acquiring an additional 6,986 shares during the period. Empirical
Here's Why AbbVie (ABBV) is a Strong Growth Stock
zacks.com
2026-02-24 10:46:15Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com
2026-02-24 10:00:31Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
prnewswire.com
2026-02-24 08:00:00NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026.
This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
fool.com
2026-02-24 08:00:00AbbVie's dividend yield is far above the market's, and the dividend has been growing for years.
AbbVie Inc. $ABBV Shares Bought by Compound Planning Inc.
defenseworld.net
2026-02-24 05:24:45Compound Planning Inc. grew its position in AbbVie Inc. (NYSE: ABBV) by 25.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,807 shares of the company's stock after acquiring an additional 3,853 shares during the quarter. Compound Planning Inc.'s holdings in AbbVie
Chase Investment Counsel Corp Increases Position in AbbVie Inc. $ABBV
defenseworld.net
2026-02-24 05:24:44Chase Investment Counsel Corp raised its position in shares of AbbVie Inc. (NYSE: ABBV) by 614.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,872 shares of the company's stock after purchasing an additional 29,990 shares during the period. AbbVie makes
Market Today: Tariffs, AI Jitters; LLY, MRK, WBD in Focus
gurufocus.com
2026-02-23 17:39:00Guru Stock PicksBernard Horn has made the following transactions:Reduce in XSWX: BARN by 39.89%Sold out in CGAdd in TSN by 18.45%New position in HKSE:01299Stock
AbbVie to invest $380 million to expand US manufacturing in Illinois
reuters.com
2026-02-23 12:03:07AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its neuroscience and obesity medicines.
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
prnewswire.com
2026-02-23 11:00:00Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade Two new facilities will be built to add advanced manufacturing capabilities to support the production of next-generation neuroscience and obesity medicines Construction will begin in spring 2026, with the site fully operational in 2029 NORTH CHICAGO, Ill., Feb. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus.
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
zacks.com
2026-02-23 09:16:08JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
Hillsdale Investment Management Inc. Trims Holdings in AbbVie Inc. $ABBV
defenseworld.net
2026-02-23 06:24:44Hillsdale Investment Management Inc. decreased its stake in shares of AbbVie Inc. (NYSE: ABBV) by 48.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 9,238 shares of the company's stock after selling 8,770 shares during the period. Hillsdale Investment Management Inc.'s holdings in AbbVie
Channing Capital Management LLC Increases Stake in AbbVie Inc. $ABBV
defenseworld.net
2026-02-22 05:38:43Channing Capital Management LLC lifted its position in AbbVie Inc. (NYSE: ABBV) by 10.5% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,647 shares of the company's stock after acquiring an additional 5,302 shares during the quarter. Channing
First Look: Nvidia beats, Stellantis pivots, WBD bid war
gurufocus.com
2026-02-26 07:39:00Stock News Nvidia posts record quarter, upbeat outlook: Nvidia (NVDA) reported Q4 revenue of $68.13B with data center sales at $62.3B (91% of total) and guided
Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
seekingalpha.com
2026-02-26 07:30:11Merck & Co. (MRK) is upgraded to buy, driven by improving dividend cushion ratio (DCR) and robust FQ4 2025 earnings recovery. MRK's dividend safety strengthens, with a projected DCR of 2.57x for 2026, surpassing both its historical average and ABBV's outlook. AbbVie (ABBV) maintains strong results but faces DCR pressure from CAPEX plans, with a projected 2.19x DCR in 2026.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More
247wallst.com
2026-02-25 07:57:47Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a "Meltdown Monday." Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology... Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More.
AbbVie Inc. $ABBV Shares Bought by Empirical Asset Management LLC
defenseworld.net
2026-02-25 05:40:42Empirical Asset Management LLC increased its position in AbbVie Inc. (NYSE: ABBV) by 206.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,372 shares of the company's stock after acquiring an additional 6,986 shares during the period. Empirical
Here's Why AbbVie (ABBV) is a Strong Growth Stock
zacks.com
2026-02-24 10:46:15Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com
2026-02-24 10:00:31Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
prnewswire.com
2026-02-24 08:00:00NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026.
This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
fool.com
2026-02-24 08:00:00AbbVie's dividend yield is far above the market's, and the dividend has been growing for years.
AbbVie Inc. $ABBV Shares Bought by Compound Planning Inc.
defenseworld.net
2026-02-24 05:24:45Compound Planning Inc. grew its position in AbbVie Inc. (NYSE: ABBV) by 25.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,807 shares of the company's stock after acquiring an additional 3,853 shares during the quarter. Compound Planning Inc.'s holdings in AbbVie
Chase Investment Counsel Corp Increases Position in AbbVie Inc. $ABBV
defenseworld.net
2026-02-24 05:24:44Chase Investment Counsel Corp raised its position in shares of AbbVie Inc. (NYSE: ABBV) by 614.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,872 shares of the company's stock after purchasing an additional 29,990 shares during the period. AbbVie makes
Market Today: Tariffs, AI Jitters; LLY, MRK, WBD in Focus
gurufocus.com
2026-02-23 17:39:00Guru Stock PicksBernard Horn has made the following transactions:Reduce in XSWX: BARN by 39.89%Sold out in CGAdd in TSN by 18.45%New position in HKSE:01299Stock
AbbVie to invest $380 million to expand US manufacturing in Illinois
reuters.com
2026-02-23 12:03:07AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its neuroscience and obesity medicines.
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
prnewswire.com
2026-02-23 11:00:00Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade Two new facilities will be built to add advanced manufacturing capabilities to support the production of next-generation neuroscience and obesity medicines Construction will begin in spring 2026, with the site fully operational in 2029 NORTH CHICAGO, Ill., Feb. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus.
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
zacks.com
2026-02-23 09:16:08JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
Hillsdale Investment Management Inc. Trims Holdings in AbbVie Inc. $ABBV
defenseworld.net
2026-02-23 06:24:44Hillsdale Investment Management Inc. decreased its stake in shares of AbbVie Inc. (NYSE: ABBV) by 48.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 9,238 shares of the company's stock after selling 8,770 shares during the period. Hillsdale Investment Management Inc.'s holdings in AbbVie
Channing Capital Management LLC Increases Stake in AbbVie Inc. $ABBV
defenseworld.net
2026-02-22 05:38:43Channing Capital Management LLC lifted its position in AbbVie Inc. (NYSE: ABBV) by 10.5% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,647 shares of the company's stock after acquiring an additional 5,302 shares during the quarter. Channing